{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:43:36Z","timestamp":1790844216109,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bulcan.2018.08.017","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T08:47:24Z","timestamp":1546591644000},"page":"S23-S34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S","title":["Prophylaxie des infections post-allogreffe\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"106","author":[{"given":"Philippe","family":"Lewalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-0138","authenticated-orcid":false,"given":"Mathieu","family":"Puyade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Roth-Guepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bulcan.2018.08.017_bib0005","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcv.2016.12.008","article-title":"Infections due to alphaherpesviruses in early post-transplant period after allogeneic haematopoietic stem cell transplantation: results of a 5-year survey","volume":"87","author":"Przybylski","year":"2017","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.08.017_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/infdis\/142.3.338","article-title":"Infection with herpes simplex virus and cell-mediated immunity after marrow transplant","volume":"142","author":"Meyers","year":"1980","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.bulcan.2018.08.017_bib0020","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/asheducation-2001.1.392","author":"Sullivan","year":"2001","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1056\/NEJM198107093050202","article-title":"Acyclovir prophylaxis of herpes-simplex-virus infections","volume":"305","author":"Saral","year":"1981","journal-title":"N Engl J Med"},{"issue":"6389","key":"10.1016\/j.bulcan.2018.08.017_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/bmj.287.6389.384","article-title":"Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial","volume":"287","author":"Hann","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1083-8791(00)70051-6","article-title":"Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome","volume":"6","author":"Koc","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0045","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2141.2003.04496.x","article-title":"Varicella-zoster virus infection in adult patients after unrelated cord blood transplantation: a single institute experience in Japan","volume":"122","author":"Tomonari","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2018.08.017_bib0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bmt.1702190","article-title":"Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir","volume":"25","author":"Steer","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2018.08.017_bib0055","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bmt.1703214","article-title":"Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Kanda","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0060","first-page":"185","article-title":"Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro","volume":"1","author":"Ljungman","year":"1986","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1399-3062.2007.00247.x","article-title":"Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders","volume":"10","author":"Kim","year":"2008","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0070","first-page":"99","article-title":"Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation","volume":"85","author":"Perren","year":"1988","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0075","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2010.99","article-title":"A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4\u00a0to 24\u00a0after BMT","volume":"46","author":"Klein","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2010.70","article-title":"Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT","volume":"46","author":"Vigan\u00f2","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","article-title":"Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hammond","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2018.08.017_bib0090","doi-asserted-by":"crossref","first-page":"21455","DOI":"10.3390\/ijms151121455","article-title":"Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment","volume":"15","author":"Nakamoto","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.bulcan.2018.08.017_bib0095","doi-asserted-by":"crossref","first-page":"O694","DOI":"10.1111\/1469-0691.12611","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome","volume":"20","author":"Mikulska","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.bulcan.2018.08.017_bib0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.bbmt.2011.04.006","article-title":"Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus","volume":"17","author":"Park","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0105","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.29022","article-title":"Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study","volume":"65","author":"Seto","year":"2017","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.bulcan.2018.08.017_bib0110","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmi.2017.06.023","article-title":"Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper","volume":"23","author":"Sarmati","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0115","first-page":"1","article-title":"Hepatitis B reactivation in patients receiving targeted therapies","author":"Chang","year":"2017","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)","volume":"16","author":"Mallet","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"Liver EAFTSOT","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.08.017_bib0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2015.328","article-title":"A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience","volume":"51","author":"Shang","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.bmt.1703139","article-title":"Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Ljungman","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2018.08.017_bib0145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.bbmt.2005.07.007","article-title":"Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies","volume":"11","author":"Martino","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2018.08.017_bib0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0002-9343(97)00007-7","article-title":"Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience","volume":"102","author":"Bowden","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0155","article-title":"Community respiratory virus infections in bone marrow transplant recipients: the M.D Anderson Cancer Center experience","volume":"7","author":"Champlin","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0160","first-page":"437","article-title":"Influenza A virus infections among hospitalized adult bone marrow transplant recipients","volume":"13","author":"Whimbey","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0165","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1086\/425004","article-title":"Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy","volume":"39","author":"Nichols","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.bulcan.2018.08.017_bib0170","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3324\/haematol.2011.041913","article-title":"Outcome of pandemic H1N1\u00a0infections in hematopoietic stem cell transplant recipients","volume":"96","author":"Ljungman","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bulcan.2018.08.017_bib0175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/tid.12054","article-title":"European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN","volume":"15","author":"Engelhard","year":"2013","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2012.08.015","article-title":"A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation","volume":"19","author":"Karras","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00259435","article-title":"The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients","volume":"10","author":"Stoutenbeek","year":"1984","journal-title":"Intensive Care Med"},{"issue":"7","key":"10.1016\/j.bulcan.2018.08.017_bib0190","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/cis580","article-title":"Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"55","author":"Taur","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0195","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1258506","article-title":"The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation","volume":"6","author":"Routy","year":"2017","journal-title":"Oncoimmunology"},{"issue":"339","key":"10.1016\/j.bulcan.2018.08.017_bib0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2311","article-title":"Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice","volume":"8","author":"Shono","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0205","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1084\/jem.20112408","article-title":"Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation","volume":"209","author":"Jenq","year":"2012","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185265","article-title":"The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation","volume":"12","author":"Weber","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bulcan.2018.08.017_bib0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006342","article-title":"The microbiome in hematopoietic stem cell transplant recipients and cancer patients: opportunities for clinical advances that reduce infection","volume":"13","author":"Koh","year":"2007","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-6143.2004.00649.x","article-title":"Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation \u2013 A randomized, double-blind trial","volume":"5","author":"Rayes","year":"2005","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0225","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw178","article-title":"Duration of colonization with klebsiella pneumoniae carbapenemase-producing bacteria at long-term acute care hospitals in Chicago, Illinois","volume":"3","author":"Haverkate","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0230","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1046\/j.1365-2141.2002.03457.x","article-title":"Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey","volume":"117","author":"Engelhard","year":"2002","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bulcan.2018.08.017_bib0235","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.bmt.1705964","article-title":"Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance","volume":"41","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0240","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/tid.12268","article-title":"Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Torda","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"10.1016\/j.bulcan.2018.08.017_bib0245","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood.V95.12.3683","article-title":"Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants","volume":"95","author":"Kulkarni","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0250","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann","year":"2016","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0255","first-page":"378","article-title":"Role of isoniazid prophylaxis for prevention of tuberculosis in haemopoietic stem cell transplant recipients","volume":"55","author":"Ahmed","year":"2005","journal-title":"J Pak Med Assoc"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0260","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1399-3062.2004.00068.x","article-title":"Tuberculosis in allogeneic stem cell transplant recipients: still a problem in the 21st century","volume":"6","author":"Erdstein","year":"2004","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-0711-6-16","article-title":"Infections caused by mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplant, a twelve year retrospective study","volume":"6","author":"Al-Anazi","year":"2007","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"10.1016\/j.bulcan.2018.08.017_bib0270","doi-asserted-by":"crossref","first-page":"e0173250","DOI":"10.1371\/journal.pone.0173250","article-title":"The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: high incidence compared with general population","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0275","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1097\/TP.0000000000001224","article-title":"Prevention and management of tuberculosis in transplant recipients: from guidelines to clinical practice","volume":"100","author":"Mu\u00f1oz","year":"2016","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0280","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0285","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/bmt.2015.316","article-title":"The incidence, mortality and timing of pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis","volume":"51","author":"Williams","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0290","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1093\/jac\/dkx198","article-title":"Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii","volume":"72","author":"Robin","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0295","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/INF.0000000000000946","article-title":"Safe and effective prophylaxis with bimonthly intravenous pentamidine in the pediatric hematopoietic stem cell transplant population","volume":"35","author":"Levy","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/tid.12486","article-title":"Retrospective review of intravenous pentamidine for pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Diri","year":"2016","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0305","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1086\/317471","article-title":"Toxoplasmosis after hematopoietic stem cell transplantation","volume":"31","author":"Martino","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0310","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QCO.0000000000000169","article-title":"Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations","volume":"28","author":"Gajurel","year":"2015","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2018.08.017_bib0315","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000380757","article-title":"Atovaquone for prophylaxis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation","volume":"134","author":"Mendorf","year":"2015","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0320","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.hemonc.2017.05.013","article-title":"Complications of hematopoietic stem transplantation: fungal infections","volume":"10","author":"Omrani","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0325","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010)","volume":"40","author":"Lortholary","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0330","series-title":"Antimicrobial. Resistance: global report on surveillance","author":"Organization WHO","year":"2014"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0335","series-title":"BEH","first-page":"121","article-title":"\u00c9pid\u00e9miologie de l\u2019aspergillose invasive en France\u00a0: r\u00e9sultat du r\u00e9seau SAIF (2005\u20132007)","author":"Lortholary","year":"2013"},{"issue":"7","key":"10.1016\/j.bulcan.2018.08.017_bib0340","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001\u20132010","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0345","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s15010-017-1016-1","article-title":"A review of infectious complications after haploidentical hematopoietic stem cell transplantations","volume":"45","author":"Atilla","year":"2017","journal-title":"Infection"},{"issue":"24","key":"10.1016\/j.bulcan.2018.08.017_bib0350","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0355","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.017_bib0360","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2010.038463","article-title":"Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients","volume":"96","author":"Cordonnier","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bulcan.2018.08.017_bib0365","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.017_bib0370","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00277-014-2259-x","article-title":"Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic\/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation","volume":"94","author":"Brissot","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2018.08.017_bib0375","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients","volume":"47","author":"Marchetti","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2018.08.017_bib0380","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.bulcan.2018.08.017_bib0385","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.bulcan.2018.08.017_bib0390","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1155\/2014\/340586","article-title":"Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective","volume":"25","author":"Laverdiere","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0395","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-89-6-893","article-title":"A prospective study","volume":"89","author":"Buckner","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bulcan.2018.08.017_bib0400","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJM198302103080602","article-title":"Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment","volume":"308","author":"Storb","year":"1983","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2018.08.017_bib0405","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF01969527","article-title":"Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation","volume":"9","author":"Vossen","year":"1990","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.bulcan.2018.08.017_bib0410","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1182\/blood.V80.10.2668.2668","article-title":"Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation","volume":"80","author":"Beelen","year":"1992","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2018.08.017_bib0415","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V93.10.3267.410k22_3267_3275","volume":"93","author":"Beelen","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2018.08.017_bib0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105706","article-title":"Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation","volume":"9","author":"Vossen","year":"2014","journal-title":"PLoS One"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:30:11Z","timestamp":1757791811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118303059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0007455118303059"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.08.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylaxie des infections post-allogreffe\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}